drugset / Trial / NCT02138786

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation

NCT02138786

Phase 2 Terminated 27 enrolled Karyopharm Therapeutics Inc
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, phase 2, single arm, open-label study of oral selinexor monotherapy in patients with Richter's Transformation, arising in the setting of prior chronic lymphocytic leukemia (CLL), after at least one chemo-immunotherapy regimen for CLL.

Timeline

Start
2014-11-14
Primary completion
2016-08-31
Completion
2016-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Selinexor Other / unclassified 60 mg/m2 Oral
Subject Selinexor Other / unclassified 80 mg Oral